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Metronomic chemotherapy  
in breast cancer
ABSTRACT
New effective therapies are under development in breast cancer; at the same time attempts are being made 
to modify the schedules of administration and doses of already available drugs. The major challenge is to treat 
patients with multiple comorbidities, who are not candidates for standard chemotherapy. An alternative for these 
patients may be a metronomic chemotherapy, which is based on continuous administration of drugs at very low 
doses every day or in short intervals. This also causes antiangiogenic and immune-modulating effects. The toler-
ance of the metronomic therapy is better, which improves the patients’ quality of life. More and more data indicate 
the use of multidrug metronomic regimens in a broader group of breast cancer patients.
This article discusses the use of metronomic chemotherapy in patients with metastatic breast cancer and focuses 
on the best established regimens of potential use as first-line therapy in elderly patients with comorbidities, who 
do not need a rapid response to therapy. Published data support also the consideration of the use of multi-drug 
metronomic chemotherapy in wider group of breast cancer patients. The course of research in this approach 
has been outlined in patients undergoing adjuvant therapy and receiving maintenance treatment in patients with 
triple-negative breast cancer.
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Introduction
Chemotherapy is important option of systemic treat-
ment for patients with different breast cancer subtypes, 
including early and advanced stages of the disease. 
Standard chemotherapy protocols consist of periodically 
repeated cycles (usually every 2–4 weeks) with cytotoxic 
drugs administered in so-called maximum tolerated 
doses. Intervals between subsequent cycles are intended 
to allow regeneration of normal proliferating cells that 
are also damaged by chemotherapy (particularly — bone 
marrow or mucosa). However, at the same time tumour 
cells may repopulate and develop chemoresistance. For 
many years research has been conducted on new and 
more effective methods of treatment (including targeted 
molecular therapies) and better use of already available 
cytotoxic drugs. Metronomic chemotherapy is another 
strategy that is based on continuous administration 
of the drug(s) at low dose. The goal of metronomic 
therapy is to achieve comparable or better efficacy and 
tolerability as compared to standard chemotherapy [1]. 
This article summarises the current state of the art 
regarding metronomic chemotherapy in breast cancer 
patients. The results of the most important clinical trials 
in patients with advanced breast cancer are discussed, 
as well as new directions for research on use of metro-
nomic chemotherapy.
Mechanism of action of metronomic 
chemotherapy
There are several mechanisms potentially respon-
sible for the effectiveness of metronomic chemo-
therapy; one of the best recognised is antiangiogenic 
effect [2]. Good vascularisation is one of the factors 
Oncology in Clinical Practice
2017, Vol. 13, No. 4, 161–168
DOI: 10.5603/OCP.2017.0018
Translation:  
dr n. med. Dariusz Stencel 
Copyright © 2017 Via Medica
ISSN 2450–1654
162
OncOlOgy in clinical practice 2017, Vol. 13, No. 4
needed for cancer growth. Standard chemotherapy 
regimens include treatment-free intervals lasting 
several weeks, during which both reconstruction of 
tumour tissue and neoangiogenesis can occur. Sev-
eral basic studies have shown that low-dose cytotoxic 
therapy reduces the proliferation of endothelial cells 
within the tumour. Their neoangiogenic potential is 
reduced, and expression of thrombospondin 1 (TSP-1) 
(angiogenesis inhibitor encoded by the THBS-1 gene) 
is increased, resulting in inhibition of progenitor 
endothelial cell mobilisation. Increased perfusion of 
blood and repair of altered blood vessels in cancer 
lesions are observed [2].
Another mechanism of action of metronomic chem-
otherapy is related to the direct effect on tumour cells, 
which consists of direct action on tumour stem cells and 
inhibition of the expression of hypoxia-inducible factor 
1a (HIF1a) [3]. 
Metronomic chemotherapy stimulates immune 
system functions, including maturation of dendritic 
cells, as well as intensification of antigen presentation 
processes and cytotoxicity of immune effector cells. The 
number and immunosuppressive potential of circulating 
regulatory T-cells is also decreased [2]. 
The three main aforementioned mechanisms of 
action of metronomic chemotherapy complement each 
other, leading to better cancer control.
Metronomic chemotherapy  
in metastatic breast cancer
Chemotherapy should be considered in all patients 
with disseminated breast cancer [4]. In patients with 
luminal subtype of breast cancer, chemotherapy is used 
in the case of hormone resistance. In HER2-positive 
cancers cytotoxic drugs are used in combination with 
HER2 inhibitors. On the other side, chemotherapy is 
still the only standard therapeutic option of systemic 
treatment in patients with triple-negative breast cancer. 
The European School of Oncology-European Soci-
ety of Medical Oncology Advanced Breast Cancer 3 
(ESO-ESMO ABC3) consensus recommends preferring 
monotherapy in patients with indications to chemo-
therapy. Multi-drug therapy should only be consid-
ered in case of rapid disease progression, presence of 
life-threatening metastases, or a need for rapid control 
of “highly symptomatic” disease. Anthracyclines or 
taxanes are among the drugs used in the first-line setting, 
but in some patients capecitabine or vinorelbine could 
also be considered. Apart from prolonging survival, the 
impact on quality of life is of the greatest importance in 
the treatment of patients with metastatic breast cancer 
and should always be taken into account when selecting 
regimens and drug doses.
Capecitabine and vinorelbine are available in 
oral form (vinorelbine is also available in intravenous 
form). A number of clinical trials have been conducted 
with the abovementioned drugs used in metronomic 
regimens. Previous studies also assessed the value of 
cyclophosphamide, methotrexate, and etoposide.
Monotherapy
Capecitabine is typically used for two weeks (two 
doses of 1250 mg/m2 = 2500 mg/m2 per day) fol-
lowed by a one-week break. In a study by Stockler et 
al. [5] 323 patients with advanced breast cancer were 
randomly assigned to three groups in which standard 
dose of capecitabine (1000 mg/m2 twice daily on days 
1–14 every 21 days), capecitabine in a metronomic regi-
men (650 mg/m2 twice daily on days 1–21 every 21 days), 
or classic CMF regimen (oral cyclophosphamide 
100 mg/m2 on days 1–14, methotrexate intravenously 
40 mg/m2, and fluorouracil intravenously 600 mg/m2 on 
days 1 and 8 every 28 days) was used in the first-line set-
ting [5]. Capecitabine was superior to CMF chemother-
apy regimen for overall survival [OS: 22 vs. 18 months, 
hazard ratio (HR) = 0.72, 95% confidence interval 
(CI) = 0.55–0.94; p = 0.02]. There was no difference in 
efficacy and toxicity of capecitabine depending on the 
dosage regimen (standard or metronomic). Another 
non-inferiority phase II clinical study involving 195 pa-
tients with disseminated HER2-negative breast cancer 
failed to confirm these results [6]. The effectiveness 
of the metronomic regimen (800 mg/m2 twice daily on 
days 1–21 every 21 days) assessed after one year was 
slightly worse than standard therapy (1250 mg/m2 twice 
daily on days 1–14 every 21 days); the percentage of 
progression-free patients was 25.3% and 27.3%, re-
spectively (95% CI = 11.5–15.5, assuming statistically 
significant result to 15%). Although the incidence of 
skin complications in the form of hand-foot syndrome 
(palmar-plantar erythrodysesthesia) was similar in both 
groups, CTCAE grade 3–4 adverse reactions (neutro-
paenia, thrombocytopaenia, diarrhoea, and mucositis) 
were more commonly observed in the metronomic 
chemotherapy group.
The oral dose of vinorelbine was defined in phase I 
clinical studies with advanced cancer patients as 50 mg 
triple weekly for three weeks in a 28-day regimen (met-
ronomic regimen) [7]. In another phase II clinical study 
in 34 elderly breast cancer patients vinorelbine was 
used in a first-line setting at a dose of 70 mg/m2 (weekly 
dose divided into three doses — days 1, 3 and 5/week, 
for three weeks followed by a one-week break; up to 
12 cycles). Median progression-free survival (PFS) was 
7.7 months (95% CI = 6.9–9.1 months). The disease 
control rate was 68%. Tolerability of treatment was 
good with no grade 4 toxicity, and neutropaenia (57% of 
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patients) and alopecia (79%) were the most commonly 
reported adverse events [8]. In another study including 
also elderly breast cancer patients (median age 76 years) 
oral vinorelbine was administered at a dose of 30 mg 
every other day. No grade 3–4 toxicity was reported and 
the patients’ quality of life evaluated after six months of 
treatment was better as compared to baseline. In 87% 
of patients, disease control was confirmed [9]. 
Currently, the results of the TempoBreast-1 study 
are awaited, which compared vinorelbine in a metro-
nomic regimen (50 mg triple weekly orally) with a stand-
ard treatment (first cycle — oral dose of 60 mg/m2 every 
seven days on days 1, 8, and 15 and then — in the ab-
sence of grade 3–4 side effects — an increased dose to 
80 mg/m2 weekly). The study results will allow compari-
son of antitumor efficacy and tolerability of vinorelbine 
in metronomic or standard regimen. 
Multi-drug regimens
Metronomic chemotherapy was also evaluated as 
two- or three-drug regimens. In one of the first clinical 
trials, 63 patients underwent chemotherapy with cyclo-
phosphamide (50 mg daily) and methotrexate (2.5 mg 
twice daily on day 1 and 2/week) [10], but the results 
were not encouraging. In total 32% of patients achieved 
some benefit. 
Several studies have been performed using vinorel-
bine and capecitabine administered orally in a met-
ronomic regimen. In the VICTOR-1 clinical study 
a maximum dose of oral vinorelbine was defined as 
40 mg triple weekly in combination with capecitabine 
500 mg triple daily on a continuous basis [11]. The study 
involved 34 patients (median age 73 years) with 74% of 
them diagnosed as ER/PgR(+). In total 76% of patients 
received previously up to one line of chemotherapy. Tol-
erability was very good, with only single cases of grade 
3–4 adverse events. Clinical benefit was reported in 58% 
of patients. Median PFS was 18.5 months. 
In another VICTOR-2 clinical trial (with the dos-
age the same as in the VICTOR-1 study) the primary 
endpoint was clinical benefit rate in patients treated 
in a first- or second-line setting [12]. In 65% of study 
participants breast cancer was diagnosed with ER/PgR 
expression, and 35% of patients had a triple-negative 
breast cancer. Disease control rate was 70%. Median 
time to progression (TTP) was similar in both groups 
and was approximately seven months. Treatment toler-
ability was good [11]. 
The results of the XeNa study indicate that ef-
ficacy of doublet metronomic regimen including vi-
norelbine (50 mg triple weekly, orally) and capecitabine 
(2000 mg/m2 daily on days 1–14 every three weeks) is 
comparable with the standard regimen (oral vinorelbine 
60 mg/m2 on day 1 and 8 and then 80 mg/m2, capecitabine 
2000 mg/m2 daily on days 1–14 every three weeks) [13]. 
In addition, patients with metronomic chemotherapy 
reported lower incidence of leukopaenia, neutropaenia, 
nausea, and neuropathy. Clinical benefit rates were com-
parable and accounted for 41% and 37%, respectively.
I n  a n o t h e r  c l i n i c a l  s t u d y  c a p e c i t a b i n e 
(828 mg/m2 twice daily on days 1–14 every three weeks) 
was evaluated in combination with cyclophosphamide 
(33 mg/m2 twice daily on days 1–14 every three weeks) in 
first- or second-line treatment for patients with advanced 
HER2-negative breast cancer [14]. Clinical benefit 
was achieved by 58% of 51 study participants. Me-
dian PFS was 12.3 months (10.7 months in patients 
with triple-negative breast cancer and 13.2 months in 
ER-positive breast cancer patients with ER expression). 
Grade 3 adverse events occurred, included leukopaenia 
(26%), neutropaenia (16%), and anaemia (2%).
Metronomic chemotherapy regimens with three 
drugs have also been developed. The VEX phase II 
clinical study included 108 patients with HER2-negative 
breast cancer [15]. In the first-line setting vinorelbine 
was administered at the dose 40 mg triple weekly in 
combination with cyclophosphamide 50 mg once daily 
and capecitabine 500 mg triple daily. Median time to 
progression (TTP) — primary study endpoint — in 
previously untreated and treated patients was 25 and 
11 months, respectively. No grade 4 toxicity was ob-
served. Clinical benefit rate was 88% in previously 
untreated patients and 81% in the group of previously 
treated for metastatic disease. The results of a study are 
very encouraging due to favourable tolerability; the most 
common grade 2 complications in previously untreated 
patients include leukopaenia and neutropaenia (37% 
and 23%, respectively), whereas in patients undergoing 
previous palliative chemotherapy the most common 
were hand-foot syndrome and neutropaenia (19% and 
12%, respectively). Non-haematological grade 3 adverse 
events included hand-foot syndrome and reversible 
transaminase elevations (5% each). 
Metronomic chemotherapy in combination  
with targeted therapies
Metronomic chemotherapy has also been studied in 
combination with bevacizumab. Treatment outcomes in 
combination with paclitaxel compared to capecitabine 
and metronomic cyclophosphamide were similar [16]. 
The incidence of adverse events also did not differ 
between the groups apart from risk of alopecia, which 
was lower in patients treated with metronomic regimen. 
The attempts are also being made to combine 
metronomic chemotherapy with anti-HER2 drugs. In 
a small phase II clinical study 22 previously treated pa-
tients with disseminated HER2-positive breast cancer 
received cyclophosphamide (50 mg daily), methotrex-
164
OncOlOgy in clinical practice 2017, Vol. 13, No. 4
ate (2.5 mg twice daily on days 1 and 4 per week), and 
trastuzumab (6 mg/kg of body weight) [17]. Clinical 
benefit was achieved in 46% of patients. Median PFS 
was six months. The toxicity was generally mild with 
grade 2 leukopaenia as the most common side effect 
(14% of patients).
Metronomic chemotherapy has also been studied 
in combination with hormone therapy. In a study with 
33 postmenopausal patients with ER-positive advanced 
breast cancer, previously treated with multiple treatment 
lines, the efficacy of fulvestrant (250 mg intramuscularly 
every four weeks) was evaluated in combination with 
metronomic chemotherapy with cyclophosphamide 
(50 mg daily) and methotrexate (2.5 mg twice daily, on 
day 1 and 4 weekly) [18]. Clinical benefit was detected 
in 56% of patients. No severe adverse effects were 
reported. 
There are also attempts to combine metronomic 
chemotherapy with other drugs (erlotinib, thalidomide, 
vandetanib, neratinib) [19–22].
Meta-analysis 
Recently, a meta-analysis of 22 clinical trials evalu-
ating metronomic chemotherapy in 1360 patients with 
metastatic breast cancer has been performed [23]. 
Objective response and clinical benefit rates were 34% 
and 56%, respectively. The proportion of patients 
without disease progression after six months was 57%, 
and one-year and two-year survival rates were 70% and 
40%, respectively. Grade 3/4 toxicity occurred in 30% of 
patients. No significant difference was found according 
to the drug used and the number of drugs (monotherapy 
vs. multi-drug regimens). On the other hand, a trend 
towards lower toxicity was observed in patients treated 
with monotherapy. 
ABC3 and SIOG recommendations regarding 
metronomic chemotherapy
According to ESO-ESMO ABC3 recommendations, 
metronomic chemotherapy is a well-established method 
of treatment for patients with advanced breast cancer 
[4]. The efficacy and toxicity profile are very encour-
aging. Above all, it should be considered in patients 
having no need for rapid response to the treatment. 
According to the guidelines, the greatest amount of 
evidence supports the use of CM regimen (cyclophos-
phamide + methotrexate, with both drugs administered 
orally at low doses). There are clinical trials ongoing, 
which are evaluating other drugs (including capecit-
abine and vinorelbine). It was highlighted that clinical 
trials comparing metronomic regimens with standard 
chemotherapy are needed. The International Society 
of Geriatric Oncology (SIOG) recommendations also 
indicate that metronomic chemotherapy is a valuable 
treatment method for elderly patients [24].
Metronomic chemotherapy in early  
and locally advanced breast cancer
According to current St Gallen and ESMO 
guidelines, adjuvant chemotherapy is primarily used 
in patients with HER2-positive or triple-negative 
breast cancer [25, 26]. On the other side, in a cohort 
with ER/PgR-positive breast cancer postoperative 
chemotherapy should be considered in patients with 
luminal B subtype (in luminal A subtype — only in 
patients at high risk of recurrence, i.e. with metastases 
in ≥ 4 axillary lymph nodes). In recent years neoadjuvant 
(preoperative) chemotherapy has been increasingly 
used in patients with primary operable breast cancer 
[HER2-positive (with use of anti-HER2 therapy) and 
triple-negative subtypes]. This way of management 
allows for a larger proportion of patients to undergo 
breast conserving surgery (BCS). At the same time, it 
is possible to evaluate a treatment response. The most 
commonly used cytotoxic drugs for standard periopera-
tive chemotherapy include anthracyclines [AC regimen 
(doxorubicin + cyclophosphamide) given every two or 
three weeks] followed by taxanes (paclitaxel — 12 infu-
sions weekly or docetaxel four cycles every three weeks). 
Adjuvant or preoperative chemotherapy is administered 
for several months. General health state (performance 
status — PS) of patients eligible for a treatment must 
allow scheduled therapy to be carried out with good 
relative dose intensity (RDI).
Preoperative (neoadjuvant) chemotherapy
Some patients are not eligible for standard perio-
perative chemotherapy due to comorbidities and poor 
PS. In this group, attempts to use alternative treatment 
methods are being made.
In a clinical trial involving 114 elderly women (over 
70 years of age) with hormone-dependent breast cancer 
in half of them cyclophosphamide (50 mg daily) was 
used for six months in addition to preoperative hormone 
therapy with letrozole [27]. Higher response rate was 
reported in patients with metronomic chemotherapy 
(88% vs. 72%). However, the overall pathologic com-
plete response (pCR) rates were comparable in both 
groups (3.5% each). After two years the percentages 
of disease-free patients were also similar in both groups 
(82% in the letrozole group and 83.5% in the group 
receiving letrozole with cyclophosphamide). 
In another small study involving 29 patients with 
locally advanced breast cancer, who were not eligible 
for standard preoperative chemotherapy due to co-mor-
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bidities or concerns of complication, cyclophosphamide 
(50 mg daily for 16 weeks) was used in combination 
with pegylated liposomal doxorubicin (20 mg/m2 every 
two weeks — eight cycles) [28]. In total 90% of patients 
were diagnosed with ER-positive breast cancer, and 
76% of patients completed the planned treatment. All 
patients underwent surgical treatment; however, only in 
one patient was pathological complete response (pCR) 
confirmed. No grade 4 toxicity was observed. Grade 
3 side effects included hand-foot syndrome, other skin 
complications, and constipation.
Clinical studies have also been conducted to evalu-
ate the hypothesis of greater efficacy of metronomic 
chemotherapy as compared to standard regimens. The 
SWOG-0012 clinical study involved 372 patients with 
inflammatory or locally advanced breast cancer (51% 
with ER-positive and 25% with HER2-positive) [29]. 
Patients were randomly assigned to two groups receiving 
five cycles of AC (doxorubicin 60 mg/m2 + cyclophos-
phamide 600 mg/m2; every three weeks) or doxorubicin 
(24 mg/m2, 15 infusions weekly) with oral cyclophospha-
mide (60 mg/m2 daily for 15 weeks) with concomitant 
febrile neutropenia prophylaxis with filgrastim. Then, in 
both groups 12 cycles of weekly paclitaxel were admin-
istered and patients underwent surgery. Overall pCR 
rate, the study’s primary endpoint, was similar in both 
groups (20.7% — standard arm vs. 24.3% — metronomic 
chemotherapy arm). There were also no significant 
differences in DFS and OS. Standard chemotherapy 
protocol was more toxic, although the proportion of 
patients who discontinued treatment shortly after 
initiation of therapy was greater in the metronomic 
chemotherapeutic group (10% vs. 2% in the standard 
arm). Grade 4 adverse events occurred in 10% and 35% 
of patients, respectively.
There have also been attempts made to add met-
ronomic chemotherapy to standard regimens in order 
to intensify treatment. In a single-arm study with 
triple-negative breast cancer patients after four cycles 
of ECF regimen (epirubicin + cisplatin + fluorouracil 
every three weeks) paclitaxel with cyclophosphamide 
(50 mg daily) was used for 12 weeks [30]. Very encourag-
ing results have been achieved — overall pCR rate was 
56%. Grade 3 adverse reactions included neutropaenia, 
leukopaenia, anaemia, and mucositis.
Postoperative chemotherapy
One of the widely used chemotherapy regimens that 
includes cytotoxic drug administered metronomically is 
CMF, with its efficacy comparable to the AC regimen 
[31]. Due to its good toxicity profile CMF can be also 
used in elderly patients. 
The International Breast Cancer Study Group 
(IBCSG) conducted the CASA study with 77 elderly 
patients to compare the efficacy and tolerability of 16-
-week treatment with pegylated liposomal doxorubicin 
(20 mg/m2 every two weeks) with a CM regimen combin-
ing cyclophosphamide (50 mg daily) and methotrexate 
(2.5 mg twice daily on days 1 and 4. weekly) [32]. In total 
68% of patients in the doxorubicin group and 83% of 
patients undergoing CM chemotherapy completed the 
treatment. Less than 50% of patients in each group 
required dose modifications. Adverse reactions were 
reported in 97% of study participants, including grade 
3 adverse reactions in 51% of patients treated with 
doxorubicin (mostly hand-foot syndrome) and 34% 
of patients given the CM protocol (most commonly 
hypertension). There was no difference in the risk of 
recurrence of breast cancer depending on the chemo-
therapy regimen used. 
CASA results are the basis for ESMO recommenda-
tions to consider both chemotherapy regimens in elderly 
patients with less functional reserve [26]. However, it 
should also be noted that there are no clinical trials 
comparing these regimens with standard protocols used 
in a population with better general health state.
Metronomic chemotherapy as maintenance 
treatment in aggressive breast cancers
A very interesting direction of breast cancer research 
is the use of additional treatment in patients with aggres-
sive subtypes of breast cancer in view of unsatisfactory 
results of standard therapies.
Several clinical studies have been conducted with ad-
ditional use of capecitabine in breast cancer patients un-
dergoing standard pre- or postoperative chemotherapy 
and surgical treatment. In several studies capecitabine 
was used metronomically. In two studies in patients with 
triple-negative breast cancer capecitabine was addition-
ally used following adjuvant chemotherapy.
In the first single-arm, phase II clinical study 
41 patients after adjuvant chemotherapy (six cycles 
of FEC100) received capecitabine 500 mg twice daily 
for the next six months [33]. In total 92% of patients 
were diagnosed with stage II or III breast cancer. 
After 34 months of observation the median DFS was 
not reached. Adverse reactions were not significantly 
increased (mostly of grade 1 of severity) — hand-foot 
syndrome (32%), vomiting (12%), or diarrhoea (5%) 
were noted [33].
In the second study, involving 19 patients with triple-neg-
ative breast cancer (with metastases in axillary lymph nodes 
or tumour size > 1 cm), capecitabine was administered 
at the dose of 650 mg/m2 twice daily for 12 months [34]. 
Previously, patients underwent adjuvant chemotherapy 
according to FAC, FEC, or FEC-taxoid protocols. The 
proportion of patients without symptoms after two and 
three years was 88% and 82%, respectively. No patient 
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Table 1. The most commonly used metronomic chemotherapy regimens in breast cancer patients
Drug/protocol Doss and schedule Comment
Monotherapy Capecitabine 650 mg/m2 twice daily on a continuous  
basis
Efficacy and toxicity comparable with standard 
regimen
Vinorelbine 50 mg orally triple weekly Results of TempoBreast study are awaited, 
comparing metronomic regimen with standard 
dosage
Doublet 
protocols
CM Cyclophosphamide 50 mg daily and 
methotrexate 2.5 mg twice daily on day 
1 and 2 per week
Clinical benefit rate = 32%
Capecitabine  
+ vinorelbine
Vinorelbine 40 mg orally triple weekly, 
capecitabine 500 mg triple daily on 
continuous basis
Clinical benefit rates 60–70%, the study involved 
patients with luminal and triple-negative breast 
cancer
Triplet 
protocols
VEX Vinorelbine 40 mg orally triple weekly, 
cyclophosphamide 50 mg daily and 
capecitabine 500 mg triple daily
Previously untreated patients: median time 
to progression = 25 months, clinical benefit 
rate — 88%, Previously treated patients 
due to cancer recurrence: median time to 
progression = 11 months, clinical benefit rate — 81%
required capecitabine dose reduction. Grade 3 hand-foot 
syndrome and diarrhoea were reported in 5% of patients.
There are phase III clinical trials ongoing to evaluate 
the efficacy of metronomically used capecitabine within 
maintenance treatment. 
CM protocol was also evaluated in the same in-
dication. In 158 patients with triple-negative breast 
cancer (tumour size > 1 cm or lymph node metastases) 
FEC → docetaxel protocol was used (control group) 
or FEC → docetaxel + carboplatin regimen followed 
by CM protocol (cyclophosphamide 50 mg daily and 
methotrexate 2.5 mg twice daily on days 1 and 2 per 
week) for 12 months [35]. Median DFS in the control 
and experimental group was 23.5 and 28 months, respec-
tively (p = 0.05), and median OS was 29 and 37 months, 
respectively (p = 0.04). The most commonly observed 
adverse reactions were neutropaenia (17–19% of grade 
3 events in both groups). In addition, in an experimental 
arm febrile neutropenia, nausea and vomiting, and diar-
rhoea were slightly more frequent. It should be noted, 
however, that complications in the experimental group 
could be related to the use of carboplatin. 
The results of a large, phase III clinical study IBCSG 
22-00 have recently been published, assessing the value 
of maintenance chemotherapy with complementary use 
of metronomic CM regimen [36]. The study involved 
1086 patients with triple-negative breast cancer (T1–4, 
N0/+) and 19% of patients with HER2-positive breast 
cancer. The dosage of the drugs in this regimen was the 
same as in the aforementioned study (cyclophosphamide 
50 mg daily and methotrexate 2.5 mg twice daily on 
days 1 and 2 per week) for 12 months. After a median 
follow-up of almost seven years, no significant difference 
was found in breast cancer recurrence rate in the whole 
population (five-year DFS rate was 74.7% in the control 
group and 78.1% in the experimental arm). The biggest 
difference was noted in patients with triple-negative 
breast cancer with axillary lymph node metastases, but 
still this did not reach statistical significance (340 pa-
tients, 64.6% and 72.5%, respectively). Nevertheless, 
the benefit of maintenance treatment was significant 
when ≥ 75% of the planned CM dose was given. Grade 3 
adverse reactions were reported in 14% of patients in the 
experimental arm (most often elevated transaminases 
and leukopaenia). 
Summary 
Metronomic chemotherapy is an attractive thera-
peutic option due to additional antiangiogenic effect, 
while at the same time being less toxic as compared to 
standard chemotherapy. The results of many clinical 
trials have been published, especially in patients with 
metastatic breast cancer. Based on the results, one can 
state that the metronomic regimen of highest value is 
CM. Capecitabine and vinorelbine, which can also be 
used in combination, are increasingly well-established. 
High response rates were obtained using the three-drug 
VEX scheme (Tab. 1). 
Metronomic chemotherapy should be considered 
primarily in elderly patients with worse performance 
status, and if rapid response to therapy is not needed. 
Metronomic chemotherapy is a valuable treatment op-
tion for patients with luminal breast cancers undergoing 
palliative chemotherapy (after hormone resistance). 
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There is extensive research ongoing on metronomic 
chemotherapy used during the perioperative period. 
Metronomic regimens could in future be an alternative 
for patients with the burden of multiple health problems, 
in whom standard doses of chemotherapy cannot be 
used. In addition, metronomic chemotherapy can find 
its place as a maintenance treatment in the most aggres-
sive subtypes of breast cancer; however, this requires 
confirmation in subsequent clinical trials.
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